MARINOMED BIOTECH AG [CBOE] overview

EQS-News: Marinomed Biotech AG / Announcement of the Convening of the General Meeting Marinomed Biotech AG: Invitation to the 7th Annual General Meeting on Thursday, June 20, 2024, at 13:00 (Vienna time) 23.05.2024 / 09:00 CET/CEST Announcement of the Convening of the General Meeting, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Invitation to the 7 th Annual General Meeting on Thursday, June 20, 2024, at 13:00 (Vienna...

EQS-News: Marinomed Biotech AG / Key word(s): Quarter Results Marinomed Biotech AG announces results for the first quarter of 2024 22.05.2024 / 07:45 CET/CEST The issuer is solely responsible for the content of this announcement. Marinomed Biotech AG announces results for the first quarter of 2024 Revenues for the first quarter 2024 declined to pre-pandemic levels of EUR 0.7 million driven by high customer stock levels and return of seasonality Q1 2024: New partnerships for Carragelose and...

EQS-News: Marinomed Biotech AG / Key word(s): Alliance Marinomed Biotech AG enters Solv4U R&D collaboration with Brazilian pharmaceutical company Aché Laboratórios 25.04.2024 / 07:45 CET/CEST The issuer is solely responsible for the content of this announcement. Marinomed Biotech AG enters Solv4U R&D collaboration with Brazilian pharmaceutical company Aché Laboratórios Marinomed will apply the Marinosolv solubilization technology to improve target compounds with the goal of developing...

EQS-News: Marinomed Biotech AG / Key word(s): Annual Results Marinomed Biotech AG announces results for the 2023 financial year and reports progress with Marinosolv and Carragelose assets 16.04.2024 / 07:45 CET/CEST The issuer is solely responsible for the content of this announcement. Marinomed Biotech AG announces results for the 2023 financial year and reports progress with Marinosolv and Carragelose assets Revenues for the 2023 financial year at EUR 9.2 million after pandemic-driven record...

EQS-News: Marinomed Biotech AG / Key word(s): Market Launch Marinomed Biotech AG: Launch of new allergen-blocking Carragelose product in Austria and market entry in Mexico 11.04.2024 / 07:45 CET/CEST The issuer is solely responsible for the content of this announcement. Marinomed Biotech AG: Launch of new allergen-blocking Carragelose product in Austria and market entry in Mexico Launch of new allergen-blocking nasal spray in Austria for the treatment of hay fever complements existing OTC...

EQS-News: Marinomed Biotech AG / Key word(s): Agreement Marinomed Biotech AG announces agreement with European Investment Bank (EIB) to defer repayments of the 2019 venture loan for 18 months 28.03.2024 / 07:45 CET/CEST The issuer is solely responsible for the content of this announcement. Marinomed Biotech AG announces agreement with European Investment Bank (EIB) to defer repayments of the 2019 venture loan for 18 months Agreement with the EIB provides for a deferral of all capital repayments...

EQS-News: Marinomed Biotech AG / Key word(s): Contract Marinomed Biotech AG enters new Carragelose distribution partnerships for Gulf region and Eastern Europe 26.03.2024 / 07:45 CET/CEST The issuer is solely responsible for the content of this announcement. Marinomed Biotech AG enters new Carragelose distribution partnerships for Gulf region and Eastern Europe Gulf-region specialist GAIA Healthcare FZ LLC obtains license for the marketing of Carragelose nasal sprays Expansion of Carragelose...

EQS-News: Marinomed Biotech AG / Key word(s): Personnel Marinomed Biotech AG: Lucia Ziegler new Head of Investor & Public Relations 01.03.2024 / 07:45 CET/CEST The issuer is solely responsible for the content of this announcement. Marinomed Biotech AG: Lucia Ziegler new Head of Investor & Public Relations Korneuburg, Austria, 1 March 2024 – Lucia Ziegler will take over the newly integrated "Investor & Public Relations" department at Marinomed Biotech AG (VSE:MARI) as of the beginning of March...